Abstract:
BACKGROUND:We examined the influence of prior antidepressant treatment trials on the likelihood of depressive relapse, and time to depressive relapse, during maintenance therapy of bipolar II disorder in treatment-responsive subjects who had recovered from a major depressive episode. METHODS:Data were derived from a prospective, randomized, double-blind trial of 148 adult subjects with bipolar II major depressive episode who were initially administered open-label fluoxetine monotherapy for 12 weeks. Remitters with a final Hamilton Rating Scale for Depression score of 8 or lower were then randomized to continuation therapy with either fluoxetine (n = 28), lithium (n = 26), or placebo (n = 27) for 50 additional weeks. RESULTS:An increase in the number of prior antidepressant treatment trials was significantly associated with a greater likelihood of depressive relapse for all treatment conditions taken together [odds ratio (OR) = 1.42, z = 2.49, P = 0.01] and for the 2 active treatment conditions together (OR = 1.51, z = 2.28, P = 0.02). An increase in the number of prior antidepressant trials was also associated with a trend-level shortening in the time to relapse for all treatment conditions taken together (hazard ratio = 1.15; confidence interval, 0.99-1.35; P = 0.07) and a significantly shorter time to relapse for subjects in the 2 active treatment conditions (hazard ratio = 1.30; confidence interval, 1.05-1.62; P = 0.02). CONCLUSIONS:These findings support prior evidence of a negative influence of the number of prior antidepressant treatment trials on the likelihood of response and suggest that the number of prior antidepressant trials may also be associated with a greater odds of depressive relapse, and a shorter time to relapse, during antidepressant maintenance therapy in recovered depressed subjects with bipolar II disorder.
journal_name
J Clin Psychopharmacoljournal_title
Journal of clinical psychopharmacologyauthors
Amsterdam JD,Kim TTdoi
10.1097/JCP.0000000000001049subject
Has Abstractpub_date
2019-07-01 00:00:00pages
344-350issue
4eissn
0271-0749issn
1533-712Xjournal_volume
39pub_type
临床试验,杂志文章abstract:PURPOSE/BACKGROUND:Extensive research has been conducted comparing the metabolic characteristics of older second-generation antipsychotics (SGAs); minimal data exist comparing the long-term metabolic effects of SGAs approved in the last 10 years. METHODS/PROCEDURES:A retrospective chart review of patients treated with...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0000000000001318
更新日期:2021-01-01 00:00:00
abstract::Four patients with obsessive-compulsive disorder (DSM-III and RDC) were treated in an open trial with alprazolam. Moderate to marked improvement was noted in the degree of obsessionality, anxiety with motor tension, and secondary affective changes. The mixed anxiolytic-antidepressant properties of alprazolam are theor...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:
更新日期:1985-02-01 00:00:00
abstract::The debilitation of schizophrenia (SCHZ) worsens markedly with comorbid cocaine dependence (CD) and alcohol abuse. To date, no medications have conclusively demonstrated effects against both SCHZ and CD (SCHZ + CD) simultaneously. Because of its dopamine-modulating properties, we hypothesized that aripiprazole would a...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/01.jcp.0000169419.38899.5b
更新日期:2005-08-01 00:00:00
abstract:BACKGROUND:Second-generation antipsychotics (SGAs) are commonly used to treat children with mental health conditions (MHCs) but are associated with adverse effects including obesity, hypertension, dyslipidemia, and type 2 diabetes. The mechanisms underlying these complications are unknown, but it has been suggested tha...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0000000000000956
更新日期:2018-12-01 00:00:00
abstract:INTRODUCTION:One of the major enzymes of the cytochrome P450 drug-metabolizing system, CYP2D6, shows a high degree of genetic polymorphism and variability in activity. Based on the degree of CYP2D6 activity, individuals can be broadly classified as poor metabolizers (PMs) or extensive metabolizers (EMs); the metabolism...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0b013e3181acc4dd
更新日期:2009-08-01 00:00:00
abstract::Many drugs, including alcohol and stimulants, demonstrably increase sociability and verbal interaction and are recreationally consumed in social settings. One drug, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), seems to produce its prosocial effects by increasing plasma oxytocin levels, and the oxytocin system ha...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/JCP.0000000000000314
更新日期:2015-06-01 00:00:00
abstract:PURPOSE/BACKGROUND:To add to limited evidence on the Abnormal Involuntary Movement Scale (AIMS) as a measure of tardive dyskinesia (TD) in clinical practice settings, the characteristics and correlates of AIMS scores were assessed. METHODS/PROCEDURES:Veterans with schizophrenia/schizoaffective, bipolar, or major depre...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0000000000001229
更新日期:2020-07-01 00:00:00
abstract::This paper examines the relationship between plasma concentration of antidepressant and both clinical response and adverse effects in treatment-resistant depressed adolescents. Adolescents (n = 334) with major depression who had not responded to a selective serotonin reuptake inhibitor (SSRI) were randomized to 1 of 4...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1097/JCP.0b013e318204b117
更新日期:2011-02-01 00:00:00
abstract::The assessment of adverse effects of psychiatric medications is important in clinical and research settings because they are often associated with medication discontinuation, symptom exacerbation, and reduced quality of life. Currently available assessment tools are either limited with regard to the number and variety...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0000000000000311
更新日期:2015-06-01 00:00:00
abstract::The pharmacokinetics of benzodiazepines and psychostimulants are reviewed and an overview of the kinetic principles relevant to the utilization of these drugs in infancy and childhood is provided. Newborns and premature infants can metabolize and eliminate diazepam, although the parent drug has a longer half-life and ...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:
更新日期:1983-08-01 00:00:00
abstract::The present study was conducted to derive pediatric mianserin pharmacokinetic parameters, which were compared to those from healthy young adults, and to obtain preliminary information regarding the utility of mianserin for the management of hyperkinesis in children. The sample consisted of six prepubescent children wi...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:
更新日期:1987-06-01 00:00:00
abstract::In an open clinical trial, serum concentrations of haloperidol pyridinium (C(HP+)) and reduced haloperidol pyridinium (C(RHP+)), as well as haloperidol (CH) and reduced haloperidol (C(RH)), were measured in 57 schizophrenic and schizoaffective inpatients during 6 weeks of short-term treatment. Psychopathology was moni...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004714-200004000-00014
更新日期:2000-04-01 00:00:00
abstract::The relationship of response and plasma desipramine concentrations was examined in elderly depressed patients to determine whether they were more sensitive to the antidepressant effects of the drug and whether they would respond at lower plasma concentrations than younger patients. Twenty-five inpatients over the age ...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:
更新日期:1985-08-01 00:00:00
abstract::Pregabalin is a novel compound in development for the treatment of anxiety disorders. The safety and efficacy of pregabalin for the treatment of social anxiety disorder was evaluated in a double-blind, multicenter clinical trial in which 135 patients were randomized to 10 weeks of double-blind treatment with either pr...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.1097/01.jcp.0000117423.05703.e7
更新日期:2004-04-01 00:00:00
abstract::The neurotransmitter dopamine is integrally involved in the rewarding effects of drugs, and it has also been thought to mediate impulsive behaviors in animal models. Most of the studies of drug effects on impulsive behaviors in humans have involved drugs with complex actions on different transmitter systems and differ...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/jcp.0b013e3181602fab
更新日期:2008-02-01 00:00:00
abstract::Cognitive dysfunction in patients with schizophrenia is a strong correlate of poor outcome than any other symptom domain. To have greater knowledge about the effects of antipsychotics on cognitive function, subjects of this study were healthy volunteers who had no confounding variables typically found in patients with...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/JCP.0b013e318272d10c
更新日期:2012-12-01 00:00:00
abstract::The efficacy of continuation therapy with tricyclic antidepressants has been established in a number of controlled trials. This study investigated the efficacy of continuation therapy with a relatively new antidepressant, amoxapine, using a double-blind controlled comparison with amitriptyline. Subjects met DSM-III cr...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:
更新日期:1990-10-01 00:00:00
abstract:BACKGROUND:Dopaminergic dysfunction, namely, dopamine transporter (DAT) availability variations in patients with drug-naive schizophrenia after long-term treatment, is still not well understood. The aims of the study were to explore (i) whether the DAT availability in patients with drug-naive schizophrenia differed aft...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0000000000000632
更新日期:2017-02-01 00:00:00
abstract::We discontinued fluphenazine decanoate using a double-blind, crossover random order design, in 12 recent onset clinically stable schizophrenics who had been given fluphenazine decanoate 12.5 mg intramuscularly every 2 weeks for at least 1 year prior to drug withdrawal. Each condition (drug or placebo) lasted 12 weeks....
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:
更新日期:1988-02-01 00:00:00
abstract:PURPOSE/BACKGROUND:The use of clozapine, particularly in young people, is often limited by early treatment-emergent adverse effects including drowsiness and lethargy. Concerns about adverse effects, medication adherence, and the need for blood monitoring often impede the use of clozapine in this population, leading to ...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0000000000000860
更新日期:2018-06-01 00:00:00
abstract::Over the past 10 years, knowledge gained about the pharmacokinetic profiles of valproate and carbamazepine has increased the clinical effectiveness of their use. Much of the information has been gained through their use as successful antiepileptic medications. As these agents begin to play an increasing role as mood-s...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004714-199202001-00010
更新日期:1992-02-01 00:00:00
abstract::The aim of this post-hoc analysis was to determine whether early symptom improvement with extended release quetiapine (quetiapine XR) may predict treatment outcome in patients with major depressive disorder. Data were from 6, double-blind, placebo-controlled studies of quetiapine XR (2 fixed-dose and 2 flexible-dose m...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章,meta分析
doi:10.1097/JCP.0000000000000416
更新日期:2015-12-01 00:00:00
abstract::In an open label study, two fixed doses of nifedipine (30 mg and 60 mg daily) were added to the usual antipsychotic drug treatments of 10 patients suffering from chronic schizophrenia. While no patient experienced significant improvements, statistically significant falls in Brief Psychiatric Rating Scales scores were ...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:
更新日期:1991-02-01 00:00:00
abstract::A role for serotonin in season affective disorder (SAD) has been explored with a variety of serotonergic pharmacologic agents. The authors initially hypothesized that metergoline, a nonspecific serotonin antagonist, would exacerbate depressive symptoms. In a small, open-label pilot study, the authors observed the oppo...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004714-200204000-00018
更新日期:2002-04-01 00:00:00
abstract:PURPOSE:The aim of this article is to review the recent trials of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists and positive allosteric modulators (PAMs) on the treatment of cognitive decline in schizophrenia. α7 Nicotinic acetylcholine receptor abnormalities in schizophrenia and clinical implications of α7 n...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/JCP.0000000000000859
更新日期:2018-06-01 00:00:00
abstract:OBJECTIVE:Clozapine (CLZ) has been shown to have a beneficial effect on cognition in schizophrenia in some studies and a detrimental effect in others. The relative effect and exposure to CLZ and its major metabolite-N-desmethylclozapine (NDMC)-could explain these discrepancies. METHODS:Using a validated measure of glo...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0b013e3181e69060
更新日期:2010-08-01 00:00:00
abstract::This study evaluated the impact of using long-acting injectable (LAI) antipsychotics for a longer treatment duration versus a short duration on health care resource utilization among Medicaid-insured schizophrenia patients. Schizophrenia patients 13 years or older initiating LAI antipsychotics were identified from the...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/JCP.0b013e3182a6082a
更新日期:2014-02-01 00:00:00
abstract::Twenty-eight patients with a DSM-III diagnosis of agoraphobia with panic attacks who completed a 4-month combined drug and behavioral treatment program and who were then discharged on imipramine were interviewed 1 to 5 years after being discharged. At the time of follow-up, half of the patients were medication free, e...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章
doi:
更新日期:1993-02-01 00:00:00
abstract::Transient amnesias, fugues, twilight states, automatisms, depersonalization, and furors or explosive disorders can occur in association with, or be caused by, various medications or substance-induced organic brain states. Agents capable of precipitating dissociative-like states include alcohol, barbiturates and simila...
journal_title:Journal of clinical psychopharmacology
pub_type: 杂志文章,评审
doi:
更新日期:1989-04-01 00:00:00
abstract::Remifentanil is a short-acting, esterase-metabolized opioid analgesic. This study compared the abuse liability of remifentanil with that of fentanyl and placebo in a randomized, double-blind, crossover study. Twelve recreational users of opioids received increasing doses of remifentanil (0.6, 1.2, 1.8, 2.4, and 3.0 mi...
journal_title:Journal of clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004714-200012000-00002
更新日期:2000-12-01 00:00:00